SAN DIEGO, Nov. 21, 2025 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody ...
BioAtla is a global clinical-stage biotechnology company with operations in San Diego, California, and in Beijing, China through our contractual relationship with BioDuro-Sundia, a provider of ...
SAN DIEGO, March 31, 2026 (GLOBE NEWSWIRE)-- BioAtla, Inc. (NASDAQ: BCAB or the "Company”), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic ...
BioAtla (BCAB) has entered into definitive agreements with certain institutional investors for the issuance and sale of 9,679,158 shares of its common stock in a registered direct offering. Each share ...
BioAtla Inc. Annual stock financials by MarketWatch. View the latest BCAB financial statements, income statements and financial ratios.
SAN DIEGO, April 30, 2025 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody ...
Image source: The Motley Fool. Management confirmed pursuit of a major partnership transaction targeted for completion by year-end and disclosed recent FDA alignment on the phase three trial design ...
Company achieved FDA alignment on Phase 3 Oz-V trial for the treatment of 2L+ OPSCC, which will evaluate dual primary endpoints with potential of achieving accelerated approval followed by full ...
SAN DIEGO & BEIJING & CAMBRIDGE, Mass.--(BUSINESS WIRE)--BioAtla, Inc., a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) protein ...
As of 10:21 GMT-4. Market open. SAN DIEGO, Oct. 04, 2024 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results